 SINGAPORE, Feb. 25, 2021 GLOBE NEWSWIRE -- ASLAN Pharmaceuticals Nasdaq:ASLN, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately 18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital a Citadel company. 